Becton Dickinson & Co (BDX): James F Orr , director of Becton Dickinson & Co sold 1,368 shares on May 10, 2016. The Insider selling transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were sold at $167.66 per share for a total value of $229,358.88 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 10, 2016, Alexandre Conroy (Executive Vice President) sold 11,238 shares at $165.58 per share price.On May 10, 2016, James C Lim (Executive Vice President) sold 5,257 shares at $165.60 per share price.Also, On May 9, 2016, Thomas E Jr Polen (Executive Vice President) sold 7,242 shares at $163.90 per share price.On May 9, 2016, Rebecca W Rimel (director) sold 684 shares at $163.69 per share price.
Becton Dickinson and Co: On Tuesday, May 10, 2016 heightened volatility was witnessed in Becton Dickinson and Co which led to swings in the share price. The shares opened for trading at $165.85 and hit $168.32 on the upside , eventually ending the session at $167.64, with a gain of 1.00% or 1.66 points. The heightened volatility saw the trading volume jump to 12,28,904 shares. The 52-week high of the share price is $168.32 and the company has a market cap of $35,574 M . The 52-week low of the share price is at $128.87.
Company has been under the radar of several Street Analysts.Becton Dickinson and Co is Reiterated by RBC Capital Mkts to Sector Perform and the brokerage firm has raised the Price Target to $ 169 from a previous price target of $153 .The Rating was issued on May 9, 2016.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.